tirzepatide glp 1 Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology A Major GLP-1 Drug Shortage

The weight loss, frequency of administration, low risk of hypoglycemia, and mechanism of controlling prandial blood glucose seen with GLP-1 RAs offer many advantages as an alternative to prandial insulin

What the science actually says, briefly I have spent most of this piece on the cultural and economic story rather than the pharmacology, because I think the pharmacology has been written about extensively elsewhere and the structural story has not

[7] [8] It turned out that this effect was due to a small peptide factor that behaved similarly to the synthetic peptide glycyl-L-histidyl-L-lysine (GHK)

Oral GLP1 therapy for type 2 diabetes eliminates that barrier, creating new pathways for earlier intervention and broader use

Ma, et al